A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Completed
Nexstar Pharmaceuticals
Phase 3
1969-12-31
To compare the toxicity profiles (severity and time to onset from initiation of therapy)
between daunorubicin (liposomal) and combination chemotherapy with
doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with
antiretroviral therapy. To compare the duration of responses, response rates, and times to
response.
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
Completed
Roswell Park Cancer Institute
Phase 3
1996-11-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether doxorubicin is more effective than
daunorubicin for AIDS-related Kaposi's sarcoma.
PURPOSE: Randomized double-blinded phase III trial to determine if doxorubicin is more
effective than daunorubicin in treating patients who have AIDS-related Kaposi's sarcoma.
Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer
Unknown status
University of Leicester
Phase 1
1997-12-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of liposomal daunorubicin in treating
patients who have metastatic breast cancer.
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2000-03-01
Phase I/II trial to study the effectiveness of liposomal daunorubicin and SU5416 in treating
patients who have hematologic cancer that has not responded to initial therapy. Drugs used in
chemotherapy use different ways to stop cancer cells from dividing so they stop growing or
die. SU5416 may stop the growth of hematologic cancer by stopping blood flow to the cancer
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
